Considerations for Conducting a Medication Use Evaluation of Andexanet Alfa for Reversal of Life-Threating Bleeding

Learn from experts in the field as they discuss barriers and key strategies for developing and conducting a medication-use evaluation (MUE) for the direct oral anticoagulant reversal agent, andexanet alfa. In addition to sharing the process for building a meaningful MUE, presenters will provide insights into navigating medication use evaluations with clinical controversy and local considerations.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.